Researchers have created an app—available online and for smartphones—that can determine the one-year risk of liver transplant patients dying or facing hospitalizations due to heart complications.
Liver transplant surgery is among the highest-risk cardiac surgery.
“Knowing the patient’s risk is critical to help prevent the frequent cardiac complications that accompany liver transplant surgery and to determine which patients are likely to survive the transplant,” says Lisa VanWagner, an assistant professor of medicine and preventive medicine at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician.
Liver transplant surgery is among the highest-risk cardiac surgery. Unique blood flow changes occur in patients with end-stage liver disease. During a liver transplant, massive changes in blood volume and adrenaline surges affect heart function.
“Identifying persons who are at highest risk may mean restricting transplantation so that we maximize the benefit of scarce donor organs to persons who have a lower risk of a cardiac event and are more likely to survive the stress of a liver transplant,” VanWagner says.
In those who are at higher risk, evaluation and consultation with a multidisciplinary team of physicians can help manage a wide array of cardiac conditions related to liver transplant patients.
The new app and method to establish risk is called the Cardiovascular Risk in Orthotopic Liver Transplantation (CAR-OLT). It’s intended for use in those ages 18 to 75 with liver disease who are undergoing evaluation for liver transplantation.
The app is both web-based (e.g., you can search the calculator and use it on the CAR-OLT website) or you can download the app through a smartphone (iTunes or Google Play stores).
Prior to the new risk-scoring method, physicians used several risk tools that had been developed in a non-liver transplant population. One such tool, the revised cardiac risk index, is no better at predicting cardiac risk in this population than flipping a coin (50 percent of the time the score predicts accurately, but 50 percent of the time it predicts inaccurately), VanWagner says.
The CAR-OLT method is thus the first liver transplant-specific risk tool for cardiac risk in liver transplant candidates.
Approximately one-third of liver transplant recipients will have a cardiovascular complication within the first year of a liver transplant. Recipients who experience a hospitalization for a cardiovascular complication after a liver transplant have lower chances of survival than someone who does not have a cardiovascular complication.
VanWagner and colleagues developed the cardiovascular risk prediction model from a large cardiovascular risk-in-liver-transplant cohort study published in 2017. They used 10 years of data of liver transplant recipients from a comprehensive institutional database (the Northwestern Medicine Enterprise Data Warehouse) that also was linked to data from the national Organ Procurement and Transplantation Network.
The national average one-year mortality rate after liver transplant surgery is approximately 10 percent. Prior research showed patients who have a hospitalization for a cardiovascular event within 90 days of their liver transplant surgery have twice the risk of death within one year.
Liver transplant procedures are done in approximately 6,500 people each year in the US. More than 14,000 persons are awaiting a liver transplant. This means there is a substantial proportion of people who will die waiting for a liver transplant due to a scarcity of donor livers.
Among the information needed to estimate the one-year post-liver transplant cardiovascular complication risk is the liver transplant candidate’s age, sex, race, employment status, highest education achieved, and the status of his or her liver cancer, diabetes, heart failure, atrial fibrillation, and pulmonary hypertension.
The web and mobile applications for the CAR-OLT score were developed in collaboration with the Northwestern University Behavioral Intervention Technology (BIT) Core Facility with funding supported by the Northwestern Medicine Division of Hepatology Research Fund.
A paper outlining the work appears in the journal Hepatology.
This work was supported by the National Institutes of Health grant and the American Liver Foundation. A National Institutes of Health’s National Center for Advancing Translational Sciences grant currently supports VanWagner. A National Center for Advancing Translational Sciences of the NIH research grant funds the Northwestern Medicine Enterprise Data Warehouse in part.
Source: Northwestern University